The Efficacy and Safety of Leflunomide in Patients with Active Rheumatoid Arthritis

Journal Title: Advances in Clinical and Experimental Medicine - Year 2012, Vol 21, Issue 3

Abstract

[b]Objectives[/b]. The aim of this study was to evaluate the efficacy and safety of leflunomide in patients with active rheumatoid arthritis (RA). [b]Material and Methods.[/b] The study included 100 patients (88 women and 12 men) with rheumatoid arthritis (RA). The mean age was 46.5 years and the mean duration of the disease was 10.3 years. The inclusion criteria were a Disease Activity Score (DAS28) of over 3.2, and contraindications to methotrexate or failure of treatment with methotrexate for at least 3 months. The patients that were enrolled in the study had developed lesions of various grades according to the Steinbrocker Radiological Classification. Leflunomide was administered at a dose of 20 mg per day for the whole observation period. During the monitoring appointments the duration of morning stiffness, pain and disease activity were evaluated on a visual analogue scale (VAS), as well as the number of tender and swollen joints and the DAS28 score. In compliance with the leflunomide therapy protocol, the following control tests were performed: erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hematology, creatinine and liver function tests. Safety assessment included monitoring of adverse events and laboratory test results. [b]Results. [/b]During the one-year monitoring period significant improvements were noted in 68% of the patients, expressed as a decrease of 1.2 or more in their DAS28 scores. DAS28 > 0 < 1.2 was achieved in a further 18% of the patients. No improvement was reported by 14% of the subjects. In one year of treatment leflunomide was effective in 74% of the patients with active RA. The most marked clinical improvement in the DAS28 index was noted between the third and sixth months of treatment. In the next six months ESR, CRP and DAS28 scores continued to decline steadily, but the differences were not as clear as those recorded in the previous time period. [b]Conclusions.[/b] The most commonly observed adverse events were related to the gastrointestinal tract (i.e. diarrhea and periodic increases in liver function tests), and reported hair loss. Mild to moderate adverse events were observed in 19% of the patients; they resolved spontaneously or in response to medication, and were not a reason for discontinuing therapy in any of the cases.

Authors and Affiliations

Ryszard Wiącek, Katarzyna Kolossa, Tomasz Jankowski, Sławomir Jeka, Andrzej Karmowski, Bohdan Gworys

Keywords

Related Articles

Kardiotoksyczność leczenia onkologicznego u dzieci

[b]Streszczenie [/b] Z powodu wzrostu zachorowalności na nowotwory i wydłużenia okresu przeżycia po ich leczeniu obserwuje się wzrost częstotliwości powikłań terapii przeciwnowotworowej. Jednym z najpoważniejszych jest...

Neuroprostheses for Increasing Disabled Patients’ Mobility and Control

Neuroprostheses are electronic devices using electrophysiological signals to stimulate muscles, electronic/mechanical devices such as substitutes for limbs or parts of limbs, or computers. The development of neuroprosthe...

Influence of Hygienic Preparations with a 3% Content of Ethanol Extract of Brazilian Propolis on the State of the Oral Cavity

[b]Background.[/b] One of the most important measures to be undertaken in order to fight gingivitis and periodontitis is maintenance of proper hygiene of the oral cavity. The research to improve the content of toothpaste...

Mathematical Models of Brachial Plexus Development During the Fetal Period: Clinical Aspects

[b]Background. [/b]The brachial plexus is an important anatomical structure. It can be damaged in both the perinatal and postnatal periods as a result of injury. The available literature does not provide much discussion...

Assessment of Quality of Life of Parents of Children with Osteogenesis Imperfecta

[b]Objectives.[/b] The aim of the work was an objective assessment of the quality of life of parents of children with osteogenesis imperfecta (OI) and of its determinant factors. [b]Material and Methods.[/b] The survey...

Download PDF file
  • EP ID EP156075
  • DOI -
  • Views 127
  • Downloads 0

How To Cite

Ryszard Wiącek, Katarzyna Kolossa, Tomasz Jankowski, Sławomir Jeka, Andrzej Karmowski, Bohdan Gworys (2012). The Efficacy and Safety of Leflunomide in Patients with Active Rheumatoid Arthritis. Advances in Clinical and Experimental Medicine, 21(3), 337-342. https://europub.co.uk./articles/-A-156075